## Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



سلطنة عُمان وزارة الصحة المديرية العامة للصيدلة والرقابة الدوائية مسقط

To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

**Director General of Royal Hospital** 

**Director General of Khoula Hospital** 

**Director General of Medical Supplies (MOH)** 

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 226 dated 23 15 2023 Regarding NCMDR recall of Randox Urine Liquid Control Level 2 from (mfr: Randox Laboratories Ltd).

## Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





## Sultanate of Oman **Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control** Muscat



وزارة الصحة المديرية العامية للصيدلية والرقابة الدوائية

Circular No. 226/2023 in page 1

08 -04-1445 H

23 -10-2023

## Recall of Randox Urine Liquid Control Level 2.from Randox Laboratories Ltd.

| https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=19714  Product Randox Urine Liquid Control Level 2.  Description IVD; In vitro diagnostic devices.  Manufacturer Randox Laboratories Ltd .  Local Agent Mustafa Sultan Science & Industry Co.LLC.  Catalog Number: UC5074  Code Information GTIN: 05055273207569  Batch/Lot Number: 1209UC  Expiry Date: 28 Mar 24  Manufacturing Date: 28 Apr 22  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  Action 1. Discontinue use of and discard any of the above immediately.  2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical   |   | Source       | NCMDR- National Center for Medical Devices Reporting- SFDA                                     |
|--|---|--------------|--|
| Description  Manufacturer  Local Agent  Mustafa Sultan Science & Industry Co.LLC.  Catalog Number: UC5074  Code Information GTIN: 05055273207569  Batch/Lot Number: 1209UC  Expiry Date: 28 Mar 24  Manufacturing Date: 28 Apr 22  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  Action  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  |   |              | https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=19714                         |
| Manufacturer Local Agent  Mustafa Sultan Science & Industry Co.LLC.  Catalog Number: UC5074  Code Information GTIN: 05055273207569  Batch/Lot Number: 1209UC  Expiry Date: 28 Mar 24  Manufacturing Date: 28 Apr 22  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  Action  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  |   | Product      | Randox Urine Liquid Control Level 2.   |
| Local Agent  Mustafa Sultan Science & Industry Co.LLC.  Catalog Number: UC5074  Code Information GTIN: 05055273207569  Batch/Lot Number: 1209UC  Expiry Date: 28 Mar 24  Manufacturing Date: 28 Apr 22  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  Action  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be   |   | Description  | IVD; In vitro diagnostic devices.  |
| The affected products  The affected products  Reason  Reason  Catalog Number: UC5074  Code Information GTIN: 05055273207569  Batch/Lot Number: 1209UC  Expiry Date: 28 Mar 24  Manufacturing Date: 28 Apr 22  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  1. Discontinue use of and discard any of the above immediately.  2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  |   | Manufacturer | Randox Laboratories Ltd .  |
| The affected products  Code Information GTIN: 05055273207569  Batch/Lot Number: 1209UC  Expiry Date: 28 Mar 24  Manufacturing Date: 28 Apr 22  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  Action  1. Discontinue use of and discard any of the above immediately.  2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be   |   | Local Agent  | Mustafa Sultan Science & Industry Co.LLC.  |
| Reason  Reason  Batch/Lot Number: 1209UC Expiry Date: 28 Mar 24 Manufacturing Date: 28 Apr 22  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  | 2 |              | Catalog Number: UC5074   |
| Reason  Reason |   |              | Code Information GTIN: 05055273207569  |
| Reason  Reason |   |              | Batch/Lot Number: 1209UC   |
| Reason  There is vial to vial variation resulting in some vials of the above product recovering positive for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be   |   |              | Expiry Date: 28 Mar 24   |
| Reason  for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  |   |              | Manufacturing Date: 28 Apr 22  |
| of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be   |   | Reason       |  |
| Action  Of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus method have been listed incorrectly.  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be   |   |              | for hCG. There has been a transcription error for Creatinine in the Instructions For Use (IFU) |
| Action  1. Discontinue use of and discard any of the above immediately. 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  |   |              | of the above product. The target and ranges for Creatinine for the Roche Creatinine Plus       |
| 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  |   |              | method have been listed incorrectly.   |
| 2. Contact the local agent for remedial action.  Healthcare professionals are encouraged to report any adverse events Suspected to be  |   | Action       | 1. Discontinue use of and discard any of the above immediately.                                |
|  |   |              | 2. Contact the local agent for remedial action.  |
|  |   | comments     | Healthcare professionals are encouraged to report any adverse events Suspected to be           |
|  |   |              |  |
| Device Control through the E-mail: Med-device@moh.gov.om   |   |              |  |

Dr. Mohammed Hamdan Al Rubaie Director General





